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Chemically modiﬁed nucleotides have been developed and applied into SELEX procedure to ﬁnd a novel type of aptamers to ﬁt
with targets of interest. In this study, we directly performed chemical modiﬁcation of 5-(N-benzylcarboxyamide)-2 -deoxyuridine
(called 5-BzdU) in the AS1411 aptamer, which binds to the nucleolin protein expressed in cancer cells. Forty-seven compounds
of AS1411-containing Cy3-labeled 5-BzdU (called Cy3-(5-BzdU)-modiﬁed-AS1411) were synthesized by randomly substituting
thymidines one to twelve in AS1411 with Cy3-labeled 5-BzdU. Both statistically quantiﬁed ﬂuorescence measurements and
confocal imaging analysis demonstrated at least three potential compounds of interest: number 12, 29 and 41 that signiﬁcantly
increased the targeting aﬃnity to cancer cells but no signiﬁcant activity from normal healthy cells. These results suggest that
the position and number of substituents in AS1411 are critical parameters to improve the aptamer function. In this study, we
demonstrated that chemical modiﬁcation of the existing aptamers enhanced the binding and targeting aﬃnity to targets of interest
without additional SELEX procedures.
1.Introduction
Aptamers are 60∼80mers composed of synthetic ribonu-
cleic acid (RNA) or deoxyribonucleic acid (DNA) oligonu-
cleotides that have been identiﬁed by a process called
systematic evolution of ligands by exponential enrichment
(SELEX); this process is based on high aﬃnity and speciﬁc
molecular ﬁt with targets of interest [1–3]. Aptamer have
recently been used as the preferred compounds for the
diagnosis and treatment of cancers as imaging target agents,
rather than monoclonal antibodies. They have the following
characteristics that make them more desirable: they are
inexpensive, eﬃcient, and rapidly produced, highly stable
during long-term storage, versatile molecules that can be
easily modiﬁed with imaging probes, their small size (8–
15kDa) results in a low immune risk and better penetration
into target tissues in vivo, and they have a high aﬃnity to
molecular target. There are a large number of aptamers that
target cancer-related proteins including Wilim’s tumor pro-
tein1,transcriptionfactor1,humanepidermalgrowthfactor
receptor 3, prostate-speciﬁc membrane antigene, tenascin-
C, nucleolin, pigpen, and vascular endothelial growth factor;
all of these proteins have been developed for targeting and
imaging cancers [4–11].
Chemical modiﬁcations of the ribose backbone of apta-
mer nucleotides, using 2 -amino or-ﬂuoro pyrimidines, have
been performed in situ and in vitro with the existing apta-
mers that cause resistance to nucleases and improve transfer
across membranes or speciﬁc binding to a target of interest;
however, this frequently resulted in the alteration of the stru-
cture of the aptamers and results in the loss of the properties
the aptamer [12, 13]. Therefore, recent chemical modiﬁca-
tions including 2 -O-methyl nucleotides, boranophophate2 Journal of Biomedicine and Biotechnology
internucleotide linkage, and 4 -thio-uridine or hydrophobic
groups like benzyl, pentynyl, napthyl, or tryptophan of 2 -
deoxyuridines modiﬁed at position 5 have been directly
added to the SELEX procedure. The results have shown
stable and/or high aﬃnity aptamers with electrostatic and
hydrophobic interactions of nucleic acids and their targets
[14–18]. These ﬁndings imply that the aptamers, identiﬁed
to date, might be less valuable or that the currently known
aptamers and their targets of interest should undergo
additional SELEX with the chemically modiﬁed nucleotides.
However, post-SELEX chemical modiﬁcations might be
useful by directly ameliorating the physical stability and
binding aﬃnity of the existing aptamers to their targets.
In this study, to improve the target aﬃnity of aptamers,
one of the existing aptamers, nucleolin aptamer (AS1411),
was selected for investigation. AS1411 is a guanine (G)-
rich oligonucleotide (GRO) aptamer in the G-quadruplex
structure that has been shown to exhibit antiproliferative
eﬀects by speciﬁcally binding to the nucleolin transmem-
brane protein in cancer cells [7, 19]. Chemical modiﬁcation
of the pyrimidine base backbone of the AS1411 nucleotides
wasperformedtoincreasethebindingaﬃnitytotargets.One
to 12 AS1411 thymidines were randomly substituted with 5-
(N-benzylcarboxyamide)-2 -deoxyuridine (designated as 5-
BzdU) labeled with Cy3. The targeting aﬃnity of the Cy3
labeled AS1411 containing 5-BzdU (designated as Cy3-(5-
BzdU)-modiﬁed-AS1411) was quantiﬁed; in addition, imag-
ing of the C6 (rat glioma cell line) and HeLa (human cervical
cancer cells) cells in the cancer cell line was performed.
2.MaterialandMethods
2.1. Synthesis of Cy3-(5-BzdU)-Modiﬁed AS1411. Cy3-
AS1411 and Cy3-(5-BzdU)-modiﬁed AS1411 was synthe-
sized using a Mermade 12 DNA synthesizer (BioAutomation
Manufacturing, Irving, TX, USA) by standard solid phase
phosphoramidite chemistry. 5-(N-benzylcarboxyamide)-2 -
deoxyuridine-phosphoramidite was provided by Samchully
Pharmaceutical (Seoul, South Korea). All oligonucleotide
synthesisprocedureswereperformedinhouse.Thesynthetic
oligonucleotides were puriﬁed using a Poros HQ anion
exchangecolumn(PerSeptiveBiosystems,Framingham,MA,
USA) or polyacrylamide gel electrophoresis (PAGE) system.
Anion exchange was performed by gradient elution with 1M
NaCl solution. The puriﬁed aptamers were precipitated by
ethanol and desalted using a Centricon (Millipore Bedford,
MA, USA). Finally, the desalted aptamers were resuspended
in water or phosphate buﬀered saline and sterilized by
ﬁltration through a 0.2μm syringe ﬁlter. The molecular
weightandpurityofeachaptamerwasevaluatedbyQ-TRAP
2000 ESI-MS spectroscopy (Applied Biosystems, Foster city,
CA, USA) and P/ACE 2000 capillary gel electrophoresis
(Beckman coulter. Fullerton, CA, USA).
2.2. Oligonucleotide Synthesis, Puriﬁcation, and Characteri-
zation. All oligonucleotides were synthesized on function-
alized controlled pore glass (CPG) on an automated solid
phase DNA synthesizer using 0.067M solution of the 5-
(N-benzylcarboxyamide)-2 -deoxyuridine-amidite in anhy-
drous acetonitrile. For incorporation of dA, dG, dC, and
dT residues standard phosphoramidites with excyclic amino
groups protected by benzoyl group (for dA and dC) and
isobutyryl groups (for G) were used. For incorporation of
5-(N-benzylcarboxyamide)-2 -deoxyuridine-amidite, phos-
phoramidite solution was delivered in two portions, each
followed by a 5-minute coupling wait time. Oxidation of
the internucleotide phosphate to phosphate was carried out
using an oxidizer (tetrahydrofuran (THF), pyridine, 0.02M
iodine and water) with waiting time. All other steps in the
protocol supplied by the manufacturer were used without
modiﬁcation. The coupling eﬃciencies were >97%. After
completion of the synthesis, the next step was treatment with
the cleavage solution(t-butylamine : methanol: water, 1: 1:
2) at 70
◦C for 5 hours to hydrolyze the ester linking the DNA
to the support and removal of the protective groups from the
purine and pyrimidine bases; this was followed by freezing,
ﬁltration, and speed-vac evaporation to dryness.
Crude oligonucleotides were puriﬁed by high perfor-
mance liquid chromatography (AKTA basic HPLC, XBridge
OST C18 10 × 50mm, A = 100mM buﬀer triethylam-
moniumbiocarbonate (TEAB), pH = 7, B = acetonitrile,
8% to 40% B in 20 minutes, ﬂow 5mLmin
−1,a t6 5
◦C,
l = 254 and 290nm). For annealing, unmodiﬁed and all
modiﬁed AS1411 aptamers were dissolved in potassium
phosphate (PBK), heated at 90
◦C for 5 minutes, and allowed
atroom temperatureprior to use.The Oligonucleotides were
characterized by LC ESI-MS, and their purity assessed by
HPLC and capillary gel electrophoresis (CGE).
2.3. Cell Culture. The cells, C6 (rat glioma cell line), HeLa
(human cervix cancer cells), and CHO cells (chinese hamster
ovary cell line), were maintained in DMEM (Gibco, Grand
Island, NY) supplemented with 10% fetal bovine serum
(FBS, Invitrogen, Grand Island, NY), 10U/mL penicillin
(Invitrogen, Grand Island, NY), and 10μg/mL streptomycin
in a 5% CO2 -humidiﬁed chamber at 37
◦C. The cells were
cultured in a multiwell chamber on slides overnight or for
two days till they reached about 50%–80% conﬂuence. After
the cells reached a conﬂuence of 90%–100%, the media were
aspirated from the cells with transfer pipettes and washed
with PBS (1× Phosphate Buﬀered Saline) brieﬂy. After
trypsinization, the cells were collected in standard culture
media and 1/5 of the cells were centrifuged at 1000rpm for 5
minutes and transferred into T75 ﬂask with 10mL of media.
2.4. Protein Assay. To normalize the ﬂuorescence signals
of forty-seven Cy3-(5-BzdU)-modiﬁed AS1411 compounds,
the cells treated with each compound were collected in
120μL PBS buﬀer after trypsinization, followed by BCA
protein assay (Thermo Fisher Scientiﬁc Inc. Waltham, MA).
T h ec o l l e c t e dc e l l sw e r em o v e di n t o9 6 - m i c r o p l a t ew e l l sa n d
treated with a mixture of reagent A and B (1 : 50), and
then incubated at 37
◦C for 30 minutes. After the biuret
reaction, the absorbance, at or near 562nm on the reader,
was measured on a plate.Journal of Biomedicine and Biotechnology 3
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Figure 1: Schematic diagram of the synthesis of the nucleolin aptamer containing 5-(N-benzylcarboxyamide)-2 -deoxyuridine. Z indicates
where the thymidines in AS1411 oligonucleotides were substituted with 5-(N-benzylcarboxyamide)-2 -deoxyuridine.
2.5. Fluorescence Intensity. The ﬂuorescence intensities of
forty-seven Cy3-(5-BzdU)-modiﬁed AS1411 compounds
were quantiﬁed to evaluate the targeting eﬃciency in
the C6 cells using the Varioskan Flash spectral scanning
multimode reader (Thermo Fisher Scientiﬁc Inc. Waltham,
MA; excitation: 535nm, scanning wavelength: 570nm with
a band width: 12nm). The C6 cells were seeded at a 1 × 105
cell density onto a MagnetoFACTION 24 plate (Chemicell,
GmbH, Germany) and placed in a 5% CO2 -humidiﬁed
chamber. After 24 hours, the seeded cells were incubated at
4◦C to decrease nonspeciﬁc binding over 30 minutes and
rinsed with PBS (1×), then replaced with 200μLo fT r i s
buﬀer and then each of 47 diﬀerent compounds (20nM)
treated.After30minutes at4◦C,theseededcellswerewashed
two times for 10 minutes each at RT with shaking incubation
(30rpm) and then trypsinized to detach the cells from the
surfaceoftheplate.ThecellswerethencollectedbyPBS(1×)
(120μL) and transferred into a 96-well plate (Chemicell,
GmbH, Germany) for measurement of the ﬂuorescence
intensity (100μL). The data is presented as means ± SD
calculated from quadruple wells.
2.6. Confocal Laser Microscopy Assay. Confocal microscopy
imaging with a laser scanning microscope (Carl Zeiss, Inc.,
Weimer, Germany; HFT 405/488nm, DAPI imaging: 420–
480nm, Cy3-labeled compounds: 488/543) was performed.
The cells were seeded at a 1 × 105 density onto a 12mm
sterile coverslip in a 24-well plate. After 24 hours, the cells
were incubated with the Cy3-(5-BzdU)-modiﬁed AS1411
compounds (20nM) and studied after additional staining
procedures for 30 minutes at 4◦C. To remove the unbound
conjugates,thecellswerewashedthreetimesover10minutes
using shaking incubation (30rpm) in PBS (1×)a n dﬁ x e d
with 3.7% formaldehyde solution (Sigma, Saint Louis, MO)
that was added to 200μL of the cells and incubated with
shaking incubation (20rpm) each for 20 minutes. After the
cells were washed three times with PBS, and 10 minutes
of shaking incubation, nuclear staining was performed with
a4  ,6-diamidino-2-phenylindole dihydrochloride (DAPI)
using a mounting solution (Vector Laboratories, Inc.,
Burlingame,CA).Theﬁxedcellswereplacedontoacoverslip
with 10μL of mountain solution. The confocal images were
acquired at low magniﬁcation (200×).
2.7. MTT Assay. C6 cells were seeded onto 24-well plate
at the density of 2 × 105 cell/well for 1 day and treated
and incubated with 4μM of each compounds including
numbers 12, 26, 29, and 41, the mutant, and Cy3-AS1411 for
1 day. 2mg/mL of 3-(4,5-dimethythazolz-yl)-2,5-diphenyl
tetrazolium bromide (MTT) solution was added to each
well (50μL/well) and incubated for 4 hours at 37
◦C. After
aspiration, 500 μL of DMSO was added into each well and
incubated for 10 minutes at 37
◦C. The resuspension was
read at 540nm by microreader (Tecan Spectra, Wetzlar,
Germany). Antiproliferation ratio was calculated by the
following formula: antiproliferation ratio (%) = (1−A540
of treated group)/(A540 of control group) × 100%. All
experiments were performed three times independently.
2.8.StatisticalAnalysis. Thefoldratioofﬂuorescenceactivity
for the 47 diﬀerent compounds of Cy3-(5-BzdU)-modiﬁed-
AS1411 and the mutant AS1411 was normalized to the
ﬂuorescence signals of Cy3-AS1411. The P-values were
calculated using the Student’s t-test.
3.Results and Analysis
Forty-seven diﬀerent compounds of Cy3-(5-BzdU)-
modiﬁed-AS1411 were designed and synthesized (Table 1).
The AS1411 oligonucleotides incorporated with 5-BzdU and
were labeled with Cy3 and prepared according to previously
published procedure [20]. One to twelve thymidines in
the AS1411 oligonucleotides were randomly replaced with
Cy3-labeled 5-BzdU (Figure 1). Forty-seven Cy3-(5-BzdU)-
modiﬁed oligonucleotides, Table 1, were synthesized on an
automated solid phase DNA synthesizer. A 0.1M solution
of phosphoramidite in anhydrous acetonitrile was used for
the synthesis. The overall coupling eﬃciency of the 5-(N-
benzylcarboxyamide)-2 -deoxyuridine-phosphoramidite
was >97%. All of the oligonucleotides were characterized
by LC ESI-MS and the purity was assessed by HPLC and
capillary electrophoresis (Table 1).4 Journal of Biomedicine and Biotechnology
Table 1: A list of AS1411 compounds containing 5-(N-benzylcarboxyamide)-2 -deoxyuridine.
Comp. No. Sequence (5  → 3 ) Calculated Mass Observed Mass Fold ratio P-value
1 Cy3-labeled-ZTTGGTGGTGGTGGTTGTGGTGGTGGTGG 9811.71 9812.32 1.12 .59
2 Cy3-labeled-TZTGGTGGTGGTGGTTGTGGTGGTGGTGG 9811.71 9811.72 1.04 .58
3 Cy3-labeled-TTZGGTGGTGGTGGTTGTGGTGGTGGTGG 9811.71 9811.92 1.07 .66
4 Cy3-labeled-TTTGGZGGTGGTGGTTGTGGTGGTGGTGG 9811.71 9812.27 1.62 .06
5 Cy3- labeled-TTTGGTGGZGGTGGTTGTGGTGGTGGTGG 9811.71 9811.83 1.27 .19
6 Cy3- labeled-TTTGGTGGTGGZGGTTGTGGTGGTGGTGG 9811.71 9812.38 1.94 .07
7 Cy3- labeled-TTTGGTGGTGGTGGZTGTGGTGGTGGTGG 9811.71 9812.18 0.62 .01
8 Cy3- labeled-TTTGGTGGTGGTGGTZGTGGTGGTGGTGG 9811.71 9812.22 0.97 .74
9 Cy3- labeled-TTTGGTGGTGGTGGTTGZGGTGGTGGTGG 9811.71 9812.01 0.96 .86
10 Cy3- labeled-TTTGGTGGTGGTGGTTGTGGZGGTGGTGG 9811.71 9812.1 0.6 .02
11 Cy3- labeled-TTTGGTGGTGGTGGTTGTGGTGGZGGTGG 9811.71 9812.69 1.2 .39
12 Cy3- labeled-TTTGGTGGTGGTGGTTGTGGTGGTGGZGG 9811.71 9811.78 2.44 ∗∗
13 Cy3- labeled-TZZGGTGGTGGTGGTTGTGGTGGTGGTGG 9930.82 9931.4 0.81 .11
14 Cy3- labeled-ZZZGGTGGTGGTGGTTGTGGTGGTGGTGG 9930.82 9931.24 1.04 .79
15 Cy3- labeled-TTTGGTGGTGGTGGTTGTGGTGGZGGZGG 9930.82 9931.02 0.89 .56
16 Cy3- labeled-TTTGGTGGTGGTGGTTGTGGZGGTGGZGG 9930.82 9931.1 0.86 .02
17 Cy3- labeled-TTTGGTGGTGGTGGTTGZGGTGGTGGZGG 9930.82 9931.81 0.95 .8
18 Cy3- labeled-TTTGGTGGTGGTGGTZGTGGTGGTGGZGG 9930.82 9930.93 1.07 .83
19 Cy3- labeled-TTTGGTGGTGGTGGZTGTGGTGGTGGZGG 9930.82 ∗N/A 0.65 .14
20 Cy3- labeled-TTTGGTGGTGGZGGTTGTGGTGGTGGZGG 9930.82 N/A 0.79 ∗∗
21 Cy3- labeled-TTTGGTGGZGGTGGTTGTGGTGGTGGZGG 9930.82 N/A 1.57 .17
22 Cy3- labeled-TTTGGZGGTGGTGGTTGTGGTGGTGGZGG 9930.82 9931.81 1.39 .16
23 Cy3- labeled-TTZGGTGGTGGTGGTTGTGGTGGTGGZGG 9930.82 N/A 0.94 .51
24 Cy3- labeled-TZTGGTGGTGGTGGTTGTGGTGGTGGZGG 9930.82 N/A 0.7 .03
25 Cy3- labeled-ZTTGGTGGTGGTGGTTGTGGTGGTGGZGG 9930.82 N/A 0.65 ∗∗
26 Cy3- labeled-TTTGGTGGTGGTGGZZGTGGTGGTGGZGG 10049.93 N/A 0.09 ∗∗
27 Cy3- labeled-TZZGGTGGTGGTGGTTGTGGTGGTGGZGG 10049.93 N/A 0.06 ∗∗
28 Cy3- labeled-ZZTGGTGGTGGTGGTTGTGGTGGTGGZGG 10049.93 10051.4 1.42 .02
29 Cy3- labeled-TTTGGTGGTGGTGGZZGTGGTGGTGGTGG 9930.82 N/A 1.62 .02
30 Cy3- labeled-TTTGGTGGTGGTGGZZGZGGTGGTGGTGG 10049.93 N/A 1.04 .27
31 Cy3- labeled-TTTGGTGGTGGTGGZZGTGGZGGTGGTGG 10049.93 N/A 1.37 .1
32 Cy3- labeled-TTTGGTGGTGGTGGZZGTGGTGGZGGTGG 10049.93 N/A 1.32 .05
33 Cy3- labeled-TTTGGTGGTGGZGGZZGTGGTGGTGGTGG 10049.93 N/A 1.19 .41
34 Cy3- labeled-TTTGGTGGZGGTGGZZGTGGTGGTGGTGG 10049.93 N/A 1.03 .12
35 Cy3- labeled-TTTGGZGGTGGTGGZZGTGGTGGTGGTGG 10049.93 10050.99 1.2 ∗∗
36 Cy3- labeled-TTZGGTGGTGGTGGZZGTGGTGGTGGTGG 10049.93 N/A 1.11 .26
37 Cy3- labeled-TZTGGTGGTGGTGGZZGTGGTGGTGGTGG 10049.93 N/A 1.43 .06
38 Cy3- labeled-ZTTGGTGGTGGTGGZZGTGGTGGTGGTGG 10049.93 N/A 1.17 .17
39 Cy3- labeled-TZZGGTGGTGGTGGZZGTGGTGGTGGTGG 10169.04 N/A 1.64 .01
40 Cy3- labeled-ZZTGGTGGTGGTGGZZGTGGTGGTGGTGG 10169.04 N/A 0.8 .01
41 Cy3- labeled-ZTZGGTGGTGGTGGZZGTGGTGGTGGTGG 10169.04 N/A 1.9 ∗∗
42 Cy3- labeled-ZZZGGTGGTGGTGGZZGTGGTGGTGGTGG 10288.15 10288.41 1.21 .03
43 Cy3- labeled-TTTGGTGGTGGZGGTTGZGGTGGTGGTGG 9930.82 N/A 0.89 .01
44 Cy3- labeled-TTTGGTGGZGGTGGTTGTGGZGGTGGTGG 9930.82 N/A 1.04 .77
45 Cy3- labeled-TTTGGZGGTGGTGGTTGTGGTGGZGGTGG 9930.82 N/A 1.17 .14
46 Cy3- labeled-TTTGGTGGZGGZGGTTGZGGZGGZGGTGG 10288.15 N/A 1.01 .94
47 Cy3- labeled-TTTGGZGGZGGZGGTTGZGGZGGTGGZGG 10407.26 N/A 1.11 .08
AS Cy3- labeled-TTTGGTGGTGGTGGTTGTGGTGGTGGTGG 9692.6 0 9693.85 1
Mt Cy3-labeled-TTTCCTCCTCCTCCTTCTCCTCCTCCTCC 9012.09 9012.7 0.26 ∗∗
Cy3-(5-BzdU)-modiﬁed-AS1411 derivatives contained 5-(N-benzylcarboxyamide)-2 -deoxyuridine in Z. AS indicates the original sequence of AS1411 and
Mt indicates the mutant form of AS1411. ∗∗, The value of observed mass for 49 compounds was randomly measured and N/A indicates no value available.Journal of Biomedicine and Biotechnology 5
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Figure 2: Fluorescence analysis of Cy3-(5-BzdU)-modiﬁed-AS1411 compounds targeting C6 cells. The ﬂuorescence of the 47 diﬀerent Cy3-
(5-BzdU)-modiﬁed-AS1411 compounds that were bound and targeted the nucleolin protein in the C6 cells was quantiﬁed. The X-axis
indicates numbers of compounds. AS represents the Cy3-labeled AS1411 and Mt the mutant form of the original AS1411 labeled with Cy3.
These data are presented as the means ± SD calculated from quadruple wells. All ﬂuorescence data were obtained at an excitation of 535nm
and emission of 570nm.
To determine the targeting eﬃciency of the cancers,
using 47 diﬀerent compounds of Cy3-(5-BzdU)-modiﬁed-
AS1411, the C6 cells (a rat glioma cell line) were ﬁrst
seeded at a 1 × 105 cell density onto 24-well plates. After 1
day of growth, the seeded cells were incubated with 20nM
of Cy3-labeled chemically unmodiﬁed AS1411 (designated
as Cy3-AS1411) or 20nM of each of the 47 diﬀerent
Cy3-(5-BzdU)-modiﬁed-AS1411 compounds at 4◦Cf o r3 0
minutes, to prevent nonspeciﬁc binding, and then rinsed
with PBS (×1) to remove the unbound Cy3-(5-BzdU)-
modiﬁed-AS1411 among each of the compounds in the cells
[21, 22]. The ﬂuorescence intensities of the Cy3-(5-BzdU)-
modiﬁed-AS1411 compounds, targeting the nucleolin pro-
teins expressed in the cellular membrane of the C6 cells, were
quantiﬁed and normalized by units of the cells measured by
the Bradford protein assay. Comparison of the ﬂuorescent
intensity of the Cy3-AS1411 with excitation at 488nm and
emission at 543nm showed that 30 out of the 47 diﬀerent
compounds showed either a slight increase or a signiﬁcantly
greater ﬂuorescent activity in the C6 cells (Figure 2). In
addition, 17 out of the 47 diﬀerent compounds showed
reduced ﬂuorescence signals compared to the Cy3-AS1411.
Furthermore, among the 17 compounds, numbers 26 and 27
showed much lower ﬂuorescence activity in the targeted C6
cells than the mutant AS1411, which had complete loss of
function of the AS1411.
The fold ratio for the ﬂuorescence signals of the 47
diﬀerent compounds of Cy3-(5-BzdU)-modiﬁed-AS1411
was normalized to that of the Cy3-AS1411 and showed that
seven diﬀerent compounds, numbers 4, 6, 12, 21, 29, 39,
and 41, had about a 1.5-fold or more binding aﬃnity for
the C6 cells (Table 1). In particular, number 12 compound
had approximately a 2.5-fold higher ﬂuorescent signal than
the Cy3-AS1411. Statistical analysis using the Student t-
test demonstrated that a P-value with higher than .05
was found in 18 diﬀerent compounds among the Cy3-
(5-BzdU)-modiﬁed-AS1411 including numbers 12, 29, 39,
and 41. These results imply that 5-BzdU modiﬁcation of
the numbers 12, 29, 39, and 41 compounds signiﬁcantly
increased the targeting aﬃnity for the C6 cells.
To further validate the increased binding aﬃnity of Cy3-
(5-BzdU)-modiﬁed-AS1411 by confocal microscopy analy-
sis, compounds numbers 12, 29, and 41 were incubated and
visualized in C6 cells with control compounds, number 26
(signiﬁcantly lose the targeting function of AS1411), Cy3-
AS1411 and a mutant of Cy3-AS1411 (negative control).
Twenty 20nM of each compound was targeted in the C6
cells. Comparison of the phase-contrast image and the
nuclear DAPI staining revealed that numbers 12, 29, and
41, and Cy3-AS1411 were extensively bound to the plasma
membrane of the C6 cells while the mutant Cy3-AS1411 and
number 26 compound were not clearly visualized in the C6
cells (Figure 3). The targeting aﬃnity to C6 cells, shown in
Figure 1, demonstrated that numbers 12, 29, and 41 had
better targeting aﬃnity than did Cy3-AS1411. The number
12 compound showed the highest ﬂuorescent brightness in
C6 cells.
To test functional activity of the compounds numbers
12, 29, and 41 in other cancer cells, we ﬁrst extended
cancer targeting assay by selecting another cancer cells, HeLa
(human cervix cancer cell line), and a normal healthy cell
line, CHO (chinese hamster ovary cell line). Similar results
with C6 cell quantitative ﬂuorescence intensity showed that
numbers 12, 29, and 41 had the higher binding aﬃnity for
the HeLa cells than the Cy3-AS1411, while the mutant and
the compound number 26 had no signiﬁcant ﬂuorescent
signal in HeLa cells (Figure 4(a)). Especially, the number 12
compound had approximately a 2.3-fold higher ﬂuorescent
activity in HeLa cells than the Cy3-AS1411. However, in
CHO cells, the compounds including numbers 12, 26, 29,
and 41, the mutant, and Cy3-AS1411 showed undetectable
ﬂuorescence intensity (Figure 4(a)). There was no signiﬁcant
diﬀerence in binding aﬃnity to CHO cells compared with
the mutant. Confocal microscopy analysis validated that the
compounds numbers 12, 29, and 41 had extensively and
better binding aﬃnity to the plasma membrane of the HeLa
cells than the Cy3-AS1411, while the mutant and number
26 compound were not signiﬁcantly visualized in the HeLa
cells (Figure 4(b)). As expected, the compounds including
numbers 12, 26, 29, and 41, the mutant, and Cy3-AS1411
were not clearly visualized in CHO cells (Figure 4(c)). To
test another functional activity of the chemically modiﬁed
nucleolin aptamer, we performed cell proliferation test by
MTT assay due to the fact that nucleolin aptamer has
antiproliferative eﬀects by speciﬁcally binding to the nucle-
olin transmembrane protein in cancer cells [7, 19]. 4μMo f6 Journal of Biomedicine and Biotechnology
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Figure 3: Confocal microscopy imaging of the Cy3-(5-BzdU)-modiﬁed-AS1411 targeting the C6 cells. numbers 29, 41, 12, and 26, Cy3-
AS1411, and the mutant form of AS1411 labeled with Cy3 were visualized in the C6 cells. The confocal images were magniﬁed to 200x. The
nucleus was stained by DAPI (emission: 460nm, blue color) and ﬂuorescent imaging of the targeting of the C6 cells was visualized by a red
color. Fluorescence images were acquired at an excitation of 535nm and emission of 570nm.
eachcompound,numbers12,26,29,and41,themutant,and
Cy3-AS1411 were added directly to C6 cells and incubated
for 1 day (Figure 4(d)). The compounds numbers 41 and
12 showed signiﬁcantly higher antiproliferative eﬀect than
the Cy3-AS1411, representing 55% and 65% of cell viability.
Meanwhile,cellproliferationeﬀectofthecompoundnumber
29 (75%) did not show any signiﬁcant diﬀerence from the
Cy3-AS1411 (78%).
We synthesized various compounds of Cy3-(5-BzdU)-
modiﬁed-AS1411withsingleormultiple5-BzdUstoincrease
their binding aﬃnity to nucleolin proteins in the cell
membranes of cancer cells. The quantiﬁcation of ﬂuorescent
signals demonstrated that a variety of chemically modiﬁed
AS1411 compounds using 5-BzdU had varied binding aﬃn-
ity to cancer cells. The number and position of substituents
in the AS1411 nucleotides were compared with the original
sequences of AS1411. Our statistical analysis and confocal
microscopy imaging showed that at least three compounds,
numbers 12, 29, and 41 out of 47 diﬀerent Cy3-(5-
BzdU)-modiﬁed-AS1411, resulted in a signiﬁcant increase
in targeting the C6 cells. To assess whether the number and
position of the 5-(N-benzylcarboxyamide)-2 -deoxyuridine
incorporated into AS1411 had the inﬂuence of targeting
and binding the C6 cells, the chemically modiﬁed sequences
of the 47 diﬀerent compounds of Cy3-(5-BzdU)-modiﬁed-
AS1411 were compared with regard to their ﬂuorescent
activity in targeting of the C6 cells. There are 12 thymidine
nucleotides in the AS1411 sequence that can be substituted
with 5-BzdU. A single substitution of a thymidine located at
the 4th to 6th,11th, and 12th position from the 5  terminal
siteofAS1411signiﬁcantlyincreasedthetargetingaﬃnityfor
the C6 cells (Table 1). However, replacement of the remain-
ing thymidines did not result in a signiﬁcant diﬀerence
in the binding aﬃnity for the cancer cells. Two modiﬁed
nucleotides, with one ﬁxed incorporation of 5-BzdU at the
12th thymidine, resulted in the highest binding aﬃnity to
the cancer cells and showed increased targeting aﬃnity with
the other modiﬁcations only at the 4th and 5th thymidine.
In addition, most of the double incorporated 5-BzdU at the
7th and 8th thymidine, in the AS1411 compound, produced
either a slight improvement or a signiﬁcant improvement in
the binding aﬃnity for the C6 cells. Of note was that number
26, the simultaneous substitution of the 7th,8th, and 12th
thymidine, of AS1411 with 5-BzdU, resulted in complete
loss of the binding aﬃnity for the C6 cells (Figure 5). Other
random heavy modiﬁcation of AS1411 did not result in
a signiﬁcant increase in the binding aﬃnity for the C6
cells. These ﬁndings imply that chemical modiﬁcation ofJournal of Biomedicine and Biotechnology 7
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Figure 4: Fluorescence analysis of numbers 29, 41, 12, and 26, Cy3-AS1411, and the mutant form of AS1411 labeled with Cy3. (a)
Quantitative ﬂuorescence intensity in HeLa and CHO cells. Data are represented as means ± standard error of means (∗P<. 05,∗∗ P<. 005
unpairedt-test).(b)ConfocalmicroscopyimaginginHeLacells.(c)ConfocalmicroscopyimaginginCHOcells.(d)Antiproliferationeﬀects
were measured by MTT assay. 4μM of each compounds was treated at 2 × 105 C6 cells per well. Data are represented as means ± standard
error of means ( ∗∗ P<. 005 unpaired t-test).
thymidines at the central or 3  terminal region of AS1411
with 5-BzdU forms a more stable G-quadruplex structure
via hydrophobic cavities and enhances the potential binding
aﬃnity of AS1411 for cancer cells.
The results of this study highlight the fact that chemical
modiﬁcations can directly applied to alter existing aptamers
thereby increasing their binding aﬃnity for targets without a
signiﬁcantincreaseintimeorlaborfortheSELEXprocedure.8 Journal of Biomedicine and Biotechnology
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Figure 5: Correlation between the structure and activity of the 5-BzdU-modiﬁed-AS1411. The position and structure of the chemical
modiﬁcation in numbers 12, 29, and 26 and the original sequence of AS1411 were drawn in G-quadruplex structure that normally formed
by dimerization of AS1411 aptamers to bind to nucleolin protein.
Such chemically modiﬁed aptamers could be used as a
valuable clinical tool for identifying serious cancer disease,
in a very early stage, and evaluation of cancer therapy.
However, further analysis including the study of diverse
e x i s t i n ga p t a m e r sa n dt h e i rt a r g e t sa sw e l la ss t u d yo f
resistance to enzymatic degradation, biostability in vivo, and
optimization of the number and positioning of the 5-BzdU
compounds in the sequence of the existing aptamers must
be studied before in vivo application is considered for the
detection and treatment of cancers.
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